MAIA Biotechnology (MAIA) – Heading Into 4Q After Strong Clinical Progress


Tuesday, September 22, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Phase 2 Extension Stage Has Begun Treatment At US Sites. MAIA began treating patients at three US sites in the Part C Expansion Phase of its Phase 2 THIO-101 trial. The trial tests ateganosine (aka THIO) in non-small cell lung cancer (NSCLC) and had completed the planned patient enrollment at international sites worldwide. Two additional US sites are expected to open during 2026.

Initial Data Shows Consistent Efficacy. In June 2026, MAIA announced initial efficacy data from the ongoing Phase 2 THIO-101 Part C Expansion Stage. Patients with at least one post-treatment evaluation by tumor scan showed a disease control rate (DCR) of 90.5% in the evaluable population. We believe that data consistent with Parts A and B could allow the company to apply for Accelerated Approval and Priority Review.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

GeoVax Labs (GOVX) – MVA Technology Platform Produces New Vaccine For Ebola


Thursday, September 17, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

BDBV Vaccine Construct Developed With GeoVax’s Proprietary Technology. GeoVax has developed a new vaccine construct against Bundibugyo virus (BDBV). This is the virus causing the Ebola Virus Disease (EVD) outbreak in the Democratic Republic of Congo (DRC), now the largest Ebola outbreak and the fastest-spreading outbreak in the DRC. We see this new vaccine construct as proof of principle for the GeoVax MVA technology platform and its ability to respond to infectious diseases with new vaccines.

We See This As An Example Of The MVA Technology Capabilities. GeoVax has proprietary technology based on the MVA (Modified Vaccinia Ankara) virus that it can use to develop and manufacture new vaccines. This technology provides a common foundation for developing new vaccines and responding to infectious disease outbreaks. Previous vaccines developed with the MVA technology platform can stimulate both antibody and cellular immune responses, resulting in long durability, high tolerability, and improved safety profiles.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

DLH Holdings (DLHC) – $43.7 Million Follow-On Award


Thursday, September 17, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Follow-on Order. DLH has been awarded a task order to continue providing high-quality information technology services for the National Heart, Lung, and Blood Institute. DLH has performed on this mission since 2018. The task order, valued at up to $43.7 million, includes a base period and multiple options aggregating to a two-and-a-half-year period of performance. We view this most recent award as further confirmation that the backlog of contracts and task orders is being freed up which will benefit DLH going forward.

Details. Under this task order, DLH will build on its existing implementation of artificial intelligence for IT operations and automation to improve service efficiency, system reliability, data integrity, cybersecurity, and compliance- all strengths of DLH. The Company will provide services in support of approximately 2,000 NHLBI scientific and administrative employees and contractors.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Aethlon Medical and North Immunology Agree to Merger, Bringing Atopic Dermatitis Biotech to Nasdaq

Aethlon Medical (NASDAQ: AEMD) and privately held North Immunology have entered into a definitive all-stock merger that will effectively take North public and create a Nasdaq-listed biotechnology company focused on immune and inflammatory diseases.

The combined company will operate as North Immunology, Inc. and is expected to trade under the new Nasdaq ticker NRTX. Existing North shareholders and investors participating in a concurrent financing are expected to own approximately 95.25% of the combined company, while pre-merger Aethlon shareholders are expected to own approximately 4.75%. The transaction values the combined company at approximately $346.5 million on a pro forma equity basis, including the financing.

Alongside the merger, North has secured an oversubscribed $180 million private placement backed by healthcare-focused institutional investors including Bain Capital Life Sciences, Janus Henderson Investors, Deep Track Capital, Longitude Capital, Soleus Capital, Farallon-managed funds and others. The financing is expected to fund operations into the second half of 2028 and support clinical development of North’s lead drug candidate, NOR-101. The transaction is expected to close in the first quarter of 2027, subject to shareholder, Nasdaq and other customary approvals.

A Reverse Merger Centered on North Immunology

Although the companies describe the transaction as a merger, the ownership and management structure make it functionally a reverse merger. North’s existing management team will lead the combined company, and its existing board – supplemented by new independent directors – is expected to become the board of the public entity. Aethlon’s Nasdaq listing and corporate structure provide North with a route to the public markets while the newly financed company concentrates its resources on North’s immunology pipeline.

That makes the transaction quite different from a conventional strategic acquisition in which the buyer absorbs the target’s assets and management. Here, North becomes the operating company that survives economically, while Aethlon shareholders retain a relatively small ownership stake.

Aethlon CEO James Frakes said the structure gives existing shareholders an opportunity to participate in North’s pipeline while preserving potential value from Aethlon’s legacy assets. Those legacy assets include the Hemopurifier, Aethlon’s clinical-stage blood-filtration device designed to remove cancer-promoting exosomes and certain life-threatening viruses from circulation. Aethlon shareholders immediately prior to closing are expected to receive contingent value rights, or CVRs, entitling them to potential proceeds if the Hemopurifier business is subsequently sold, licensed or otherwise monetized.

NOR-101 Becomes the Center of the Investment Story

The combined company will be built primarily around NOR-101, North Immunology’s half-life-extended bispecific antibody targeting both IL-13 and IL-18.

North is developing the drug initially for atopic dermatitis, the most common form of eczema. The chronic inflammatory skin disease can cause itching, lesions and recurring flare-ups, and moderate-to-severe cases increasingly are treated with biologic therapies or other systemic drugs.

The rationale behind NOR-101 is to attack two different components of the inflammatory response simultaneously. IL-13 is an established target associated with type 2 inflammation, while IL-18 is associated with additional inflammatory pathways. North believes blocking both could potentially address a broader spectrum of disease biology than therapies focused on type 2 inflammation alone.

The company has reported an approximately 42-day half-life in a non-human primate pharmacokinetic study, an attribute that could eventually support less frequent dosing if it translates into humans. NOR-101 remains preclinical, however, meaning the thesis still has to be demonstrated in patients.

North expects to begin a Phase 1a study in the first quarter of 2027, with interim pharmacokinetic and safety data expected by midyear. The company then plans to begin Phase 1b and Phase 2b studies in atopic dermatitis during 2027, with topline results from both studies anticipated in 2028.

Atopic Dermatitis Has Become a Highly Competitive Market

North is entering a field that offers substantial commercial opportunity but also an increasingly high clinical bar. Biologic therapies have transformed treatment of moderate-to-severe atopic dermatitis. Sanofi and Regeneron’s Dupixent, which inhibits IL-4 and IL-13 signaling, established the category, while Eli Lilly’s Ebglyss directly targets IL-13. AbbVie’s JAK inhibitor Rinvoq provides another systemic treatment option.

The strategic value pharmaceutical companies are assigning to differentiated eczema therapies was underscored this summer when AbbVie agreed to acquire Apogee Therapeutics for $10.9 billion. Apogee’s lead asset is a long-acting anti-IL-13 antibody that produced encouraging Phase 2 results and is designed in part to reduce injection frequency relative to existing biologics.

IL-18 is also attracting attention. Earlier this year, Evommune reported positive Phase 2a results for an experimental IL-18-targeting therapy in moderate-to-severe atopic dermatitis, sending its shares sharply higher following the data. Those developments provide scientific and commercial context for North’s decision to combine IL-13 and IL-18 inhibition in a single molecule, but they also demonstrate how competitive the field has become.

Differentiation Will Be Critical

Simply producing another effective eczema therapy may no longer be enough. Recent industry developments show that drugmakers are increasingly demanding meaningful improvements in efficacy, durability, convenience or safety before committing substantial additional capital to new atopic dermatitis programs.

Sanofi, for example, recently abandoned plans to seek approval for the atopic dermatitis drug amlitelimab after concluding that its clinical profile would not represent a sufficiently meaningful improvement over available therapies. Johnson & Johnson also discontinued development of an experimental eczema therapy earlier this year after an interim analysis failed to clear the company’s efficacy threshold.

That creates both the opportunity and the challenge for NOR-101. North is attempting to distinguish the candidate through dual-pathway inhibition and potentially extended dosing intervals, but investors will ultimately need human clinical data showing that those characteristics translate into meaningful improvements for patients. The first important test begins next year.

$180 Million Gives North a Longer Development Runway

The concurrent financing is an important component of the transaction. Clinical-stage biotechnology companies frequently use reverse mergers to access public markets, but the resulting companies can still face immediate capital needs. North is entering the public market with approximately $180 million of expected gross financing proceeds, including the conversion of roughly $34 million in convertible notes and related amounts.

Management expects that capital to fund operations into the second half of 2028, which would carry the company through several planned clinical milestones for NOR-101. The investor syndicate is also notable because it includes several established life sciences investors rather than relying principally on smaller retail-oriented financing sources. For investors evaluating the transaction, that does not eliminate clinical risk, but it provides North with a substantially stronger balance sheet as it enters human testing.

Aethlon Shareholders Retain Exposure to the Legacy Business

For existing Aethlon shareholders, the transaction effectively separates two investment propositions. Their 4.75% expected ownership of the combined company provides exposure to North Immunology and NOR-101, while the CVR preserves potential future value from Aethlon’s existing Hemopurifier program if those assets can be monetized.

Aethlon has been developing the Hemopurifier as an extracorporeal therapeutic device capable of depleting circulating cancer-promoting exosomes and certain viruses. The FDA has granted the technology Breakthrough Device designation in both oncology and life-threatening viral disease settings, and Aethlon has been conducting an early-stage study in solid-tumor patients receiving checkpoint inhibitors. Whether those assets ultimately generate meaningful CVR proceeds will depend on a future sale, licensing agreement or other transaction, making that component inherently uncertain.

Related Immunology Company in Noble Capital Markets Coverage

Eledon Pharmaceuticals (NASDAQ: ELDN) offers a related immunology example within Noble Capital Markets research coverage. Eledon is developing tegoprubart, an anti-CD40L antibody intended to modulate immune responses in organ and islet transplantation. Like NOR-101, its therapeutic approach targets a defined immune signaling pathway, although the diseases, mechanisms and stages of development are quite different. Eledon is covered by Noble Capital Markets.

North Immunology Prepares for the Public Markets

For Aethlon, the agreement represents a fundamental change in corporate direction. For North Immunology, it provides a Nasdaq listing, substantial new capital and a path to move its lead program into human trials without pursuing a traditional IPO.

The resulting company will bear North’s name, use its management team and focus primarily on its pipeline, making the transaction best understood as a reverse merger built around a newly financed immunology company.

The scientific thesis is straightforward: IL-13 inhibition is already validated in atopic dermatitis, while emerging research suggests additional inflammatory pathways such as IL-18 may contribute to disease in patients who remain inadequately treated. Whether simultaneously targeting both pathways can produce a differentiated therapy remains unproven.

With roughly $180 million in financing and the first NOR-101 clinical study expected to begin in early 2027, investors should not have to wait long for the combined company to begin generating the human data that will ultimately determine whether that strategy can compete in one of immunology’s most active therapeutic markets.

Release – GeoVax Confirms Bundibugyo Ebola Vaccine Construct

GeoVax, Inc.

Research News and Market Data on GOVX

BDBV-Specific Construct Developed Using GeoVax Proprietary Rapid Cloning Technology and Builds on Established Filovirus Vaccine Experience

GEO-MVA (Mpox/Smallpox Vaccine) Targeted for Phase 3 Initiation Remains Company Priority

ATLANTA, GA – September 16, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and solid tumor cancers, today announced the development of a vaccine construct targeting Bundibugyo virus (BDBV), the cause of the ongoing Bundibugyo virus disease outbreak in the Democratic Republic of Congo.

The BDBV construct was generated using GeoVax’s proprietary MVA-based rapid-cloning technology, designed to enable rapid insertion or replacement of vaccine antigens in response to emerging infectious disease threats. The construct represents a milestone step toward a potential BDBV vaccine candidate.  Full characterization and animal evaluation are necessary prior to clinical evaluation.

The BDBV work builds upon GeoVax’s existing MVA-based developmental-stage filovirus vaccine portfolio targeting Zaire Ebola virus, Sudan Ebola virus and Marburg virus. These earlier programs have generated encouraging efficacy results in established preclinical models, including nonhuman primate challenge studies, with results presented publicly and published in peer-reviewed scientific journals. This body of work provides a scientific and technical foundation for applying GeoVax’s MVA platform to BDBV.

“While GEO-MVA remains our primary development focus, the ongoing, expanding BDBV outbreak represents an opportunity to apply capabilities developed through years of MVA and filovirus research,” said David Dodd, Chairman and Chief Executive Officer of GeoVax. “The successful generation of this BDBV-specific MVA construct demonstrates the responsiveness of our platform and builds on our published preclinical experience across Zaire Ebola, Sudan Ebola and Marburg, including encouraging results in nonhuman primate challenge studies. As global organizations advance multiple BDBV vaccine approaches, we believe this combination of filovirus experience, rapid construct generation and next-generation MVA technologies warrants further evaluation.”

Growing Global Focus on BDBV Vaccine Development

Bundibugyo virus disease is a severe filovirus infection for which there is currently no licensed BDBV-specific vaccine. The World Health Organization (WHO) has called for accelerated development and evaluation of BDBV-specific vaccines and other countermeasures and has established a target product profile to guide vaccine development.

The urgency surrounding BDBV has also prompted increased global investment in vaccine development. In August 2026, the Coalition for Epidemic Preparedness Innovations (CEPI) announced funding of up to $16.5 million to advance another MVA-based BDBV vaccine candidate through preclinical development and toward an early-stage clinical trial in Africa. The program is part of a broader CEPI strategy to advance multiple BDBV vaccine approaches.

GeoVax believes its BDBV construct and extensive body of MVA-based filovirus experience may warrant consideration within this expanding global development effort. In addition to its rapid-cloning technology, GeoVax is advancing MVA technologies directed toward single-dose vaccination, continuous cell-line manufacturing and alternative delivery approaches. The Company also recognizes the importance of regional manufacturing and is committed to evaluating manufacturing partnerships, including in Africa, as part of future MVA-based vaccine development programs.

“Our BDBV work provides another tangible example of how an adaptable vaccine platform and established scientific expertise can potentially contribute to outbreak preparedness,” Dodd concluded. “We look forward to exploring opportunities with global health, government and scientific partners to further evaluate the BDBV construct and our broader filovirus capabilities.”

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on the development of vaccines and immunotherapies addressing high-consequence infectious diseases and solid tumor cancers. GeoVax’s priority program is GEO-MVA, a Modified Vaccinia Ankara (MVA)–based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026, to address critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness. In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings. GeoVax maintains a global intellectual property portfolio supporting its infectious disease and oncology programs and continues to evaluate strategic partnerships and funding opportunities aligned with its development priorities. For more information, visit www.geovax.com.

Forward-Looking Statements

This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Company Contact:

[email protected]

678-384-7220

Media Contact:

Jessica Starman

[email protected]

Release – MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial

Primary Logo

Research News and Market Data on MAIA

September 16, 2026 8:15am EDT Download as PDF

Milestone follows FDA clearance of MAIA’s amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and efficiencies 

U.S. expansion is funded by a $2.3 million NIH grant to MAIA to support third-line treatment evaluation

CHICAGO, Sept. 16, 2026 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the first U.S. patient has been dosed in its Phase 2 THIO-101 trial expansion evaluating its telomere-targeting lead candidate, ateganosine, in third-line non-small cell lung cancer (NSCLC). The U.S. Phase 2 expansion is funded by a $2.3 million grant from the National Institutes of Health (NIH) to support third-line treatment evaluation and MAIA has activated 3 sites in the U.S.

MAIA holds FDA Fast Track designation for ateganosine, a dual mechanism therapy designed to break down telomere structure and function in cancer cells while inducing immune activation. Prior data from THIO-101 Parts A and B show overall survival (OS) beyond 24 months in eight patients receiving ateganosine sequenced with a checkpoint inhibitor.

“We have worked diligently to advance ateganosine into the U.S. market, and dosing the first patient in the United States represents a major milestone for our ongoing Phase 2 clinical trial,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “Our collaborations with some of the nation’s top institutions and foremost oncologists further strengthen the trial as we evaluate ateganosine for patients in advanced stages of this exceedingly hard-to-treat disease. We believe the data generated through the THIO-101 program may also support a potential pathway toward FDA accelerated approval. With patients now enrolled across four continents, the study has evolved into a truly global effort focused on addressing a critical unmet need in cancer care.”

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About THIO-101 Phase 2 Clinical Trial

THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using Overall Response Rate (ORR) as the primary clinical endpoint. The expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo®) has shown an acceptable safety profile to date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

Investor Relations Contact
+1 (872) 270-3518
[email protected]

Primary Logo

Source: MAIA Biotechnology, Inc.

Released September 16, 2026

Xenetic Biosciences and Santersus Agree to All-Stock Combination to Create Nasdaq-Listed NET Therapeutics Company

Xenetic Biosciences (NASDAQ: XBIO) and privately held Santersus AG have entered into a definitive share exchange agreement that would combine the two biotechnology companies and create a Nasdaq-listed company focused on therapies targeting neutrophil extracellular traps, or NETs.

Under the agreement, Xenetic will acquire all outstanding shares of Santersus in exchange for newly issued Xenetic common stock. Following closing, Santersus shareholders are expected to own approximately 85% of the combined company, while existing Xenetic shareholders are expected to own approximately 15%. The combined company is expected to be renamed Santersus Bio, Inc. and trade on Nasdaq under the ticker SNTS.

Although Xenetic is technically the acquiring entity, the ownership and governance structure make the transaction more akin to a strategic combination than a conventional acquisition. Santersus shareholders will hold the large majority of the post-transaction equity, Santersus management is expected to lead the combined company, and the new board is expected to include six Santersus nominees and two Xenetic nominees.

Building a Broader NET-Targeting Platform

The strategic rationale centers on combining complementary approaches to targeting NETs.

NETs are web-like structures released by neutrophils as part of the immune response. While they can help trap pathogens, excessive or persistent NET formation has also been implicated in inflammation, thrombosis, tissue injury and disease progression across a range of conditions.

Santersus is developing NucleoCapture, a therapeutic blood-filtration platform designed to remove circulating NETs and related pathogenic components directly from the bloodstream. The company has been pursuing applications in conditions including sepsis, systemic lupus erythematosus and liver transplantation.

Xenetic brings a different approach through its DNase platform, which is designed to enzymatically degrade NETs. Xenetic has been developing this approach primarily in oncology, including as a potential way to improve the effectiveness of cancer therapies such as CAR-T by reducing the protective effects NETs may provide within the tumor microenvironment.

The combined company would therefore have both extracorporeal and biologic approaches to the same broad target, creating a portfolio that spans inflammatory disease, transplantation and oncology.

Santersus Brings the Lead Clinical-Stage Asset

Santersus’ NucleoCapture platform is expected to become the principal clinical development focus of the combined company. The technology is designed to filter NETs and other disease-associated extracellular material from circulating blood without broadly suppressing the immune system. Santersus has positioned the platform for acute and immune-mediated conditions where excessive NET formation may contribute to disease severity.

The company’s development programs include sepsis, lupus and liver transplantation, areas where treatment options can be limited and where severe inflammatory responses may cause substantial organ damage. For Xenetic, the transaction significantly broadens its development pipeline while moving the combined organization closer to clinically advanced opportunities than Xenetic would have on its own.

Governance Reflects the Economic Structure

The post-transaction governance reinforces the fact that this is not a typical buyer-target acquisition. Santersus’ leadership is expected to run the combined company, while Xenetic will contribute its Nasdaq listing, existing programs and corporate infrastructure. The board composition is also expected to tilt heavily toward Santersus, consistent with the roughly 85/15 ownership split.

That makes the transaction structurally similar to other biotech combinations in which a private company gains access to the public markets through a merger with an existing listed entity. For investors, the key point is that the future investment thesis will be driven primarily by Santersus’ clinical programs and the broader NET-targeting strategy, rather than by Xenetic’s historical business alone.

Why NET Biology Is Drawing Interest

The scientific interest in NETs has grown as researchers have linked excessive NET formation to a wide range of inflammatory, thrombotic and immune-mediated diseases. In sepsis, NETs may contribute to microvascular obstruction, inflammation and organ damage. In autoimmune disease, persistent NET formation has been associated with immune dysregulation. In transplantation, the same inflammatory mechanisms may contribute to ischemia-reperfusion injury and graft dysfunction.

That broad biological relevance creates opportunities, but it also raises an important development challenge: showing that targeting NETs can translate into meaningful clinical outcomes across specific indications. The combined Santersus/Xenetic company will need to demonstrate not only that NET burden can be reduced, but that doing so improves patient outcomes in well-defined patient populations.

A Broader Biotech Theme: Controlling Harmful Immune Responses

The transaction also fits into a wider biotechnology trend involving therapies designed to control damaging immune activity without broadly shutting down the immune system.

One related company followed by Noble Capital Markets is Eledon Pharmaceuticals (NASDAQ: ELDN). Eledon is developing tegoprubart, an anti-CD40L antibody designed to prevent immune rejection in organ and islet-cell transplantation while avoiding some of the limitations associated with conventional immunosuppressive drugs. Noble research has highlighted Eledon’s kidney-transplant and islet-transplant programs as the company advances tegoprubart through clinical development.

The mechanisms are different, but the strategic overlap is clear: both Santersus and Eledon are pursuing more targeted ways to address harmful immune activity in settings where excessive inflammation or immune rejection can drive poor outcomes.

Cadrenal Adds a Critical-Care Parallel

Another Noble-covered company with a related critical-care angle is Cadrenal Therapeutics (NASDAQ: CVKD). Cadrenal is developing therapies for serious thrombotic and cardiovascular conditions, including tecarfarin and CAD-1005. Its pipeline includes programs in heparin-induced thrombocytopenia and other acute-care settings where thrombosis and coagulation abnormalities can create significant clinical risk.

Again, the biology is different, but Cadrenal provides another example of a small-cap biotechnology company targeting severe, high-risk conditions where existing therapies may be inadequate and where improved control of inflammation, coagulation or immune dysfunction could have meaningful clinical value.

A Public-Market Reset for Xenetic

For Xenetic shareholders, the transaction represents a major reset of the company’s strategic direction. If completed, the combined company will be much more heavily defined by Santersus, both economically and operationally. Existing Xenetic shareholders will retain a minority position in a broader NET-targeting platform that includes multiple clinical indications and a new management team.

For Santersus, the agreement provides a path to the U.S. public markets and access to a Nasdaq-listed platform without pursuing a traditional initial public offering. The result is a combination designed to create a more diversified biotechnology company around a relatively focused scientific thesis: that excessive NET formation plays a meaningful role across inflammatory, transplant and oncology indications, and that directly targeting those NETs could create new therapeutic opportunities.

If the transaction closes as planned, investors will be evaluating the new Santersus Bio less as a continuation of Xenetic and more as a newly assembled NET therapeutics company with a substantially different pipeline, ownership structure and clinical focus.

Release – Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in 
DR Congo with 48% Crude Fatality Rate, Says NanoViricides

Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in 
DR Congo with 48% Crude Fatality Rate, Says NanoViricides

Research News and Market Data on NNVC

Tuesday, 15 September 2026 09:25 AM

Topic: 

Company Update

SHELTON, CT / ACCESS Newswire / September 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that its Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses in the Democratic Republic of Congo (“DRC”) is scheduled to start next week at an Ebola Treatment Center in the Ituri province.

“NV-387 being an oral drug with broad-spectrum antiviral properties, everyone is rooting for it and hoping that it is effective against Ebola in the this clinical trial,” said Anil R. Diwan, PhD, President of the Company, adding, “The Bundibugyo virus for which there is no known treatment or vaccine is causing an unprecedented, rapidly spreading, disease outbreak with a crude fatality rate as high as 48%. We hope that NV-387 can help save lives.”

Currently, a clinical trial called “PARTNERS” was started as of July 2, 20261 to evaluate two drugs that both require delivery by infusion. Approximately 300 patients have already been enrolled in this trial across four groups, namely (i) Infusion of a monoclonal antibody cocktail, MBP134, (ii) Infusion of Remdesivir, (iii) Infusion of MBP134 plus Infusion of Remdesivir, and (iv) a control group with local standard of care.

Infusions are inherently unscalable for the extent of the current ebola outbreak in the resource-poor areas in DRC. Additionally, infusion treatment also increases risks to health care workers such as needle-sticks, as well as due to patient handling and possible blood exposure.

NV-387 is currently the only orally administered drug in clinical trials to the best of our knowledge, and this is why medical professionals in the field are looking forward to success in the clinical trial of NV-387.

Oral NV-387 was compared with Intravenously given Remdesivir given in animal studies of a lethal coronavirus infection model when NV-387 was originally developed as a treatment for COVID-19. NV-387 Oral was found to be superior in extending survival of the lethally infected animals when compared to Remdesivir I.V. in this study. Therefore, the Company believes that NV-387 oral drug can be reasonably expected to provide superior activity compared to at least remdesivir infusion that is already in the PARTNERS clinical trial.

Antibodies are easily overcome by viruses in the field, as was experienced during the COVID-19 pandemic. All antibody drugs that received emergency use approvals lost efficacy within a few months due to mutations in the SARS-CoV-2, an RNA virus. Ebola Bundibugyo is an RNA virus with likely similar rates of mutation. It remains to be seen if and how long MBP134 remains effective during the current Ebola outbreak, even if found to be effective and approved, for use.

The Bundibugyo virus is highly unlikely to escape NV-387, unlike in the case of antibodies such as MBP134. This is because NV-387 mimics a portion of the cell surface that is essential for all Ebola viruses to cause productive infection, no matter how different they are.

“Comparing NV-387 to currently available therapeutics under study leads us to rationally anticipate at least partial success in the proposed clinical trial,” said Dr. Diwan, warning, “However, it is the data from the clinical trial that will tell us if NV-387 is effective and can become an important pillar in response to this Ebola Outbreak Crisis in DRC.”

The clinical trial is entitled with a descriptive title: “An adaptive, multi-centre Phase IIA/IIB clinical trial of NV-387 oral gummies plus optimised supportive care in adults with Ebola virus disease (Bundibugyo or other orthoebolaviruses): a single-arm safety and dose run-in (Phase IIA) followed by a randomised, controlled, open-label efficacy evaluation with independent blinded-endpoint adjudication (Phase IIB).” Prof. Patrick de Marie Chimusa Katoto is the principal investigator leading this clinical trial, as previously announced by the Company. Om Sai is the CRO leading the Company’s Phase II clinical trial of NV-387 Oral Gummies as a Treatment for Mpox in DRC, and the same CRO is also leading this Ebola clinical trial.

The clinical trial is registered in the Pan African Clinical Trials Registry (pactr.samrc.ac.za) database. The unique identification number for this clinical trial is PACTR202608748555077.

It is anticipated that the first Ebola patient dosing with NV-387 oral gummies under this clinical trial can be expected to occur next week, barring impediments caused by the very ebola disease outbreak that the trial is designed to respond to.

The current Ebola Virus Disease (EVD) caused by the Bundibogyo ebolavirus (BDBV) is now the largest ever ebola outbreak, as well as the fastest growing ebola outbreak in DRC.

As of September 10, 2026, there have been 7,022 confirmed cases, 3,398 confirmed deaths, and 1,671 confirmed recoveries in DRC, according to the WHO daily report 2. In comparison, as of August 14, 2026, there were reported 4,945 confirmed cases and 2,325 confirmed deaths due to this virus. The crude fatality rate (crude CFR) 3 is about 48% .

The actual probability of an infected person dying is about 67%, with about 1/3rd of patients recovering in DRC (ibid #2 footnote).

This Ebola outbreak is now the fastest growing ebola outbreak in the world. Additionally, it is also possibly the deadliest ebola outbreak. At this rate, the current outbreak is on track to exceed the worst ever ebola zaire outbreak in West Africa in 2014-2016 4. In that outbreak, 28,616 cases and 11,310 deaths were recorded across Guinea, Liberia and Sierra Leone, according to the World Health Organization.

Schools have reopened normally in the Ebola affected regions across DRC, despite the well understood risk of transmission in schools. Teaching and implementing hygienic measures such as use of hand sanitizers and frequent hand washing is expected to minimize risk, enabling the children to have in-class education. The alternative of remote learning is very difficult to implement in resource-poor environments, and risks the children’s education itself. If cases occur, schools would be shut down. The risk is high, particularly because the crude case fatality rate (CFR) in children is at 60%, much greater than the CFR for adults at sub-50% 5.

Additionally, health care workers (HCW) are at high risk, despite personal protective equipment, because of close contact with the patients. At least 43 HCWs have died from Ebola and at least 160 have contracted the disease 6.

The need for an oral drug to combat this disease is thus obvious. An oral drug to treat patients, to prevent contacts from contracting the disease, and to keep healthcare workers safe, is sorely needed to combat this outbreak. There is a tremendous urgency to validate a drug that works against this ebolavirus in short and decisive clinical trials for minimizing further spread by treating patients and for saving lives. Om Sai CRO, in consultation with renowned scientists in DRC, has designed the Phase II clinical trial with this particular objective.

An oral drug called obeldesivir, which is related to the known drug remdesivir that previously failed in clinical trials against Ebola Zaire, is being tried in a clinical trial, but only as a preventative measure, and not as a treatment of active infection.

In contrast, in the PARTNERS clinical trial, infusions of antibody cocktails and of remdesivir are being tried. This trial will require over 1,000 patients to be treated and may not yield results for several months. A similar large collaborative clinical trial effort in the West Africa 2014-2016 outbreak resulted in US FDA approval of two antibody drugs only specifically for EBOV Zaire, which are not deemed to be useful in the current outbreak without further clinical trials.

Three different vaccines are also expected to enter into clinical trials for efficacy within months, according to the WHO 7. Ervebo, a vaccine developed for Ebola Zaire, is being deployed in a research protocol to health care workers. Its efficacy against BDBV needs to be evaluated in a clinical trial, according to WHO.

As of now, there is practically no risk from this Ebola outbreak for the USA, according to the CDC. The US has imposed strict travel restrictions to avoid any possible introduction of the ebola virus into the USA. The CDC is intimately involved in the Ebola response with 150 personnel deployed within DRC for the efforts (ibid #1).

NanoViricides has retained Om Sai Clinical Research Private Limited, India, (Om Sai CRO) as the CRO for this Phase II clinical trial for Ebola in DRC. Om Sai CRO has been instrumental in putting together the team with Prof. Katoto and other renowned experts and with support from the University of Bukavu and in the Ebola-affected region to lead and execute the clinical trial of NV-387 Oral Gummies as a Treatment for Ebola viruses in DRC.

As the Ebola outbreak continues to expand, several limitations on travel are being instated. There are also limitations on availability of resources such as PPE and diagnostic kits, which are compounded by the travel and other restrictions. These on-ground situations have caused delays in our efforts, and we anticipate such delays to continue due to the tenuous outbreak situation.

This Ebola outbreak continues to increase in spread and is now present in at least six provinces in DRC and threatening South Sudan 8. More concerning is the fact that over 80% of new cases are outside of known contact lists, leading to the projection that the extent of the outbreak is at least two times or more larger than the reported confirmed cases. Additionally, Ebola is now found to have spread into displacement camps that host over 4.4 million displaced persons due to internal warfare, adding another high risk population pool with poor drinking water, sanitation and medical resources to further fuel this outbreak, according to the UN New Service.

There is no approved Treatment or Vaccine for the new variant of the Bundibugyo Ebolavirus (BDBV) that is causing the current rapidly expanding outbreak of the Ebolavirus Disease (EVD) in DRC. The rare Bundibugyo strain of Ebola virus causing the current outbreak appears to be its new variant, likely freshly introduced from some animal source 9, such as fruit bats.

“Although this antiviral (Remdesivir) proved to be ineffective at targeting the Zaire Ebolavirus, there remains hope that it could have some benefit against the Bundibugyo virus, particularly if used in combination with MBP-134,” according to an article in Forbes explaining the “PARTNERS” clinical trial by the WHO organized collaboration 10. The article also notes that MBP134 contains two separate antibodies designed to, taken together, recognize multiple Ebola species.

Antibodies are highly specific to a particular strain of the virus and usually are not very effective against variants of the same virus that arise in the field. Viruses also escape antibodies readily by mutations in the field.

NV-387 is a broad-spectrum antiviral that mimics the host-side features that the virus requires, and is likely to be effective against Ebola viruses because they use the same host-side feature mimicked by NV-387.

NV-387 Oral Gummies is a drug product readily delivered orally. It does not even require swallowing effort or water, because it dissolves in the mouth by itself, simplifying delivery for even sick individuals with swallowing difficulties.

This oral delivery is an important feature that puts NV-387, a broad-spectrum antiviral, as being superior to the other approaches.

“Only safe and effective broad-spectrum antiviral drugs like NV-387 that can effectively tackle most viral infections will enable the world to combat viruses and defend the global population in the war against known and unknown nanoscopic enemies that are viruses,” commented Dr. Diwan, adding, “Today, NV-387 is the only drug in clinical development with such broad-spectrum potential that promises to combat diverse epidemics like Mpox and Ebola, to the best of our knowledge.”

While there is currently minimal risk of Ebola in the USA, the CDC’s mathematical models suggested this Central African outbreak could grow to 10,000 to 20,000 cases and 2,000 to 4,000 deaths within just three months, rivaling the largest outbreak to date in 2014-2016 11. Unfortunately, the outbreak appears to be even more aggressive than the CDC model, with over 2,000 deaths in less than three months, over 4,000 confirmed cases, and over 10,000 estimated total cases 12.

The outbreak which was declared a Public Health Emergency of International Concern (“PHEIC”) by the WHO on May 17, 2026, continues to rapidly expand, outpacing containment efforts. The outbreak arose in a high traffic region bordering the Democratic Republic of Congo (DRC), with travel contacts to Uganda, and South Sudan and with 11 more nations in Africa at risk 13.

NV-387 is a broad-spectrum antiviral that mimics the host-side feature called heparan sulfate proteoglycan (HSPG) that over 90-95% of human pathogenic viruses require for infecting cells. No matter how much the virus changes in the field, it continues to use HSPG, and therefore it cannot escape the drug NV-387. In contrast, Remdesivir is a small molecule inhibitor of the viral RDRP enzyme needed for making copies of the viral genome, and the virus can possibly escape by small number of mutations.

All Ebola viruses utilize HSPG as the attachment receptor prior to gaining entry into the cell. Thereafter, followed by entry into the cell inside endosomes, the ebolavirus surface glycoprotein is substantially degraded, opening up its site for binding to its cognate receptor called NPC1, thereby entering into the cytoplasm where the next steps in its replication begin.

Thus there is a strong rationale that NV-387 could be highly effective against Ebola virus infections, not just Bundibugyo, but also the Sudan and other viruses for which there are no treatments.

All previous anti-Ebola efforts have been focused on vaccines and antibodies 14. This has led to approval of therapies that are specific to the Ebolavirus Zaire strain only, albeit with limited effectiveness. This leaves out all other filoviruses of consequence: Sudan, Marburg, and the more rare Bundibugyo with no treatment or vaccine.

In contrast, if NV-387, as a broad-spectrum antiviral, is found to be effective against the Bundibugyo virus, it will likely be effective against all ebolaviruses and possibly all filoviruses; that would be a game changer for pandemic preparedness.

The case fatality rate of ebolaviruses has generally been approximately 50% in recent outbreaks, with improvements in care, including hydration therapy, corticosteroids, and other usual symptomatic treatments. Ebola viruses spread via bodily fluid secretions including fomites/sputum, as well as semen/genital secretions. Ebola virus can remain in survivors even as many as 965 days after the disease without symptoms, and can transmit through bodily secretions, suggesting possible latency. Many recent outbreaks have been ignited as a result of such reawakened-transmitted virus from a survivor. Sexual transmission was documented even as late as 482 days after disease. This persistence and possible latency of ebolavirus in immune-privileged organs (e.g. brain, eyes, gonads, where antibodies are not operative) makes it a uniquely serious threat for global transmission and sustained outbreaks.

At present, BDBV has been consistently demonstrating high crude CFR of 48% in DRC. Therefore, BDBV is of great concern as a potential pandemic disease. However, it is believed that ebolaviruses do not transmit via respiratory droplets or aerosols and rather require extensive contact with bodily fluids of an infected person. In addition, within DRC and internationally, certain protective quarantine measures for travel from the outbreak areas have been implemented.

Therefore, currently there is no apparent threat of a global pandemic.

An irony is that because of the high case fatality rate (CFR) approaching 50%, the spread of ebolaviruses remains rather limited. If a variant emerges with a reduced CFR, say in the range of 5-15%, the potential threat of global pandemic from such an outbreak would increase substantially.

With ever-increasing global travel, local outbreaks such as ebola can quickly travel far and wide potentially causing global pandemics, as was the case with COVID-19, if not caught in time. It is not feasible to produce a new vaccine and a new set of antibody drugs to combat every possible virus. Even if vaccines and antibodies are produced, the virus would escape by generating variants, as the world has witnessed during the COVID-19 pandemic.

The US Government is active in ensuring that suspected or confirmed ebolavirus cases do not enter the general population in the USA. To this end, travel from DRC has been restricted, with pre-travel quarantine requirements imposed, and suspect travelers are directed to screening at specific airports and may be further quarantined.

Travelers going to and from Central Africa need to constantly check travel restrictions as well as travel limitations in light of these changing outbreak conditions.

ABOUT NANOVIRICIDES

NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
[email protected]

Public Relations Contact:
[email protected]

Source: NanoViricides, Inc.

1 https://www.reuters.com/business/healthcare-pharmaceuticals/trial-bundibugyo-ebola-treatment-starts-drc-who-says-2026-07-02/

2 https://www.who.int/emergencies/alert-and-response, retrieved on Monday September 14, 2026 at 14:10 EDT. See also, https://www.cdc.gov/ebola/situation-summary/index.html.

3 The Crude CFR is calculated simply by dividing the confirmed deaths by the confirmed number of cases on the same reporting date. It ignores the fact that the deaths are actually occurring in patients that were confirmed infected several days earlier; i.e. the time lag of sickness is not accounted for in the crude CFR. If it is accounted for, the actual fatality rate per confirmed infection (Infected Fatality Rate or IFR) would be much higher than the crude CFR. For example, if one assumes an average time lag of 21 days (Aug 14 to Sept 5), then the IFR on September 5 would be (3,175/4,945 = ) 64%. Not all infections are reported or confirmed by lab tests; however, it is likely that most deaths are counted. This produces a large uncertainty in such CFR and IFR estimates. Another way to estimate IFR would be to simply take a ratio of confirmed deaths to that of confirmed deaths plus confirmed recoveries. This metric, probability of death, is more robust and insensitive to the lag times, except it ignores patients that are still in hospital. The p(death) based on this metric is (using Sept. 10 numbers,(3,398)/(3,398 +1,671) = 67% . That said, a number of cases as well as deaths remain unconfirmed or unreported because of the regional issues.

4 https://www.telegraph.co.uk/global-health/science-and-disease/ebola-outbreak-doubling-every-20-days-warns-un-chief/

5 https://www.news4jax.com/news/world/2026/09/01/schools-resume-classes-in-congos-ebola-epicenter-despite-concerns-from-parents-and-teachers/ .

6 https://www.ft.com/content/abd30cb8-08f6-4a1a-a92b-f1fcc339ea82?syn-25a6b1a6=1&signupConfirmation=success

7 https://www.yahoo.com/news/science/articles/congo-ebola-outbreak-slows-epicentre-050000953.html

8 https://www.aljazeera.com/news/2026/7/20/ebola-death-toll-in-drc-surges-to-at-least-930-as-outbreak-gathers-pace

https://www.aljazeera.com/news/2026/7/16/ebola-spreading-more-quickly-in-drc-while-uganda-is-close-to-being-virus-free

9 https://virological.org/t/initial-genomes-from-may-2026-bundibugyo-virus-disease-outbreak-in-the-democratic-republic-of-the-congo-and-uganda/1032

10 https://www.forbes.com/sites/omerawan/2026/07/07/new-clinical-trials-offer-hope-in-the-fight-against-ebola-in-the-democratic-republic-of-congo/

11 https://www.cdc.gov/media/releases/2026/update-on-ebola-outbreak-in-the-democratic-republic-of-the-congo-and-uganda-6-5-2026.html

12 The WHO and Africa CDC have estimated that the confirmed case number substantially under-represents actual case numbers which could be at least double or even more than confirmed cases. See #5.

13 https://www.forbes.com/sites/maryroeloffs/2026/05/25/african-health-officials-on-ebola-this-is-too-much-live-updates/

14 Substantial work was also performed to develop small chemical potentially broad-spectrum agents. Remdesivir was the only small chemical that entered the PALM clinical trials ca. 2018-2019 but failed to show effectiveness. Small chemicals are readily escaped by viruses often with just single mutations.

SOURCE: NanoViricides

GeoVax Labs (GOVX) – GEO-MVA Phase 3 Trial Moves Forward With Laboratory Testing Agreement For Patient Samples


Tuesday, September 15, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Agreement With CEPI Lab Network Establishes Standardized Sample Testing. GeoVax announced an agreement with CEPI (Coalition for Epidemic Preparedness Innovations) to test patient samples from its Phase 3 GEO-MVA study through the CEPI Centralized Laboratory Network. CEPI is an internationally recognized laboratory network that uses standardized assays and laboratory methods. We see this as an important development that can provide reliable results for both regulatory approval and comparison with other therapeutics.

An Important Step For The GEO-MVA Trial. GeoVax reiterated its plan to begin its GEO-MVA immunobridging study in Mpox/smallpox in 4Q26. The trial is expected to enroll about 500 patients, with results expected in mid-2027. The EMA (European Medicines Agency) has given Scientific Advice stating that a single immune bridging study showing that an immune response elicited by the GEO-MVA vaccine is non-inferior to the approved vaccine would be sufficient to apply for approval from the European Union.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – GeoVax and CEPI Enter Agreement to Utilize CEPI Centralised Laboratory Network to Support GEO-MVA Phase 3 Trial

GeoVax, Inc.

Research News and Market Data on GOVX

Independent Evaluation Supports GEO-MVA Pivotal Phase 3 Program

Advances GeoVax’s Strategy to Expand and Diversify MVA Vaccine Supply

ATLANTA, GA – September 14, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against high consequence infectious diseases and solid tumor cancers, today announced that it has entered into a Memorandum of Agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) providing GeoVax access to clinical trial sample testing services through the CEPI Centralised Laboratory Network in support of its planned pivotal GEO-MVA Phase 3 immune-bridging study.

The agreement represents an important step in the continued development of GEO-MVA, GeoVax’s MVA-based vaccine candidate targeting mpox and smallpox. It provides access to independent laboratory testing using standardized assays and reporting procedures established through CEPI’s global laboratory infrastructure. CEPI’s network is the largest global group of laboratories dedicated to harmonizing the immunological assessment of vaccines in development against infectious diseases with epidemic and pandemic potential. With network scientists assessing clinical trial samples using the same methods and validated assays, the possibility of variability in trial readouts is minimized, helping researchers and regulators consistently evaluate vaccine performance in clinical trials. For GeoVax, the agreement also supports a broader strategic objective: building independent scientific evidence necessary to establish GEO-MVA as a potential additional source of MVA-based mpox vaccine supply at a time when outbreaks and preparedness requirements continue to demonstrate the importance of resilient, diversified vaccine capacity.

GeoVax expects to initiate its approximately 500-participant pivotal Phase 3 immune-bridging study in the fourth quarter of 2026, with results expected in mid-2027.

Recent global mpox outbreaks have underscored the risks of constrained vaccine supply and the importance of expanding MVA vaccine capacity. GeoVax believes sustainable preparedness will increasingly require not only adequate vaccine stockpiles, but also multiple qualified sources of supply and manufacturing capacity capable of serving different regions of the world.

“Independent evaluation is an important step toward building confidence in GEO-MVA among regulators, public-health organizations, governments and potential strategic partners,” said David Dodd, Chairman and Chief Executive Officer of GeoVax. “Our agreement with CEPI provides access to a highly respected global laboratory network capable of testing and characterizing immune responses associated with GEO-MVA.”

Dodd continued, “But the larger objective extends beyond development of another mpox vaccine. The global preparedness community needs resilient MVA supply. We believe that the data produced by CEPI’s network could pave the way for an additional qualified supply source of mpox vaccine supply if we are successful in testing and licensure, reducing dependence on a single manufacturing infrastructure and ultimately enabling production capacity that can be deployed closer to the populations it is intended to protect.”

Independent Evaluation Supporting an Expanded-Source Strategy

Under the agreement, clinical samples provided by GeoVax will be evaluated through the CEPI Centralised Laboratory Network using assays specific to orthopoxviruses, the family of viruses to which mpox and smallpox belong.

The independent nature of the testing is particularly important as GeoVax advances GEO-MVA toward its pivotal Phase 3 study. Results generated through CEPI’s laboratory network will provide independently generated and standardized immunological data that will inform GeoVax’s ongoing clinical development and future regulatory interactions.

“CEPI’s Centralised Laboratory Network was set up during the COVID-19 pandemic to help reduce clinical testing differences that can emerge from independent laboratory review to instead ensure easy access and alignment to key data that could support vaccine approvals” said Dr Amy Shurtleff, Director of Laboratory Research and Innovation Department at CEPI. “It has rapidly expanded since then, with vaccine developers around the world using the service to evaluate thousands of their samples produced during trials of promising vaccine candidates against other deadly pathogens, including mpox. Our new agreement with GeoVax enables the company to access validated, high-quality mpox testing tools that could fast-track its promising GEO-MVA mpox vaccine through development and give the world further options to fight this harmful, recurring disease.”

The agreement also provides a framework under which CEPI may share anonymized summaries of sample-testing results with the World Health Organization (WHO), Gavi, the Vaccine Alliance and others to further CEPI’s mission to transform the world’s response to epidemic and pandemic threats, including diseases like mpox.

GeoVax will cover the full testing costs associated with the research carried out by CEPI’s Centralised Laboratory Network. CEPI has not provided specific funding for the development of GEO-MVA.

 About GEO-MVA

GEO-MVA is GeoVax’s Modified Vaccinia Ankara (MVA)-based vaccine being developed for protection against mpox and smallpox. Following Scientific Advice from the European Medicines Agency (EMA), GeoVax is pursuing an immune-bridging development strategy that is intended to compare immune responses generated by GEO-MVA with those generated by the licensed MVA-BN comparator.

GeoVax is developing GEO-MVA to expand global access to MVA vaccine supply, scalable production capabilities, and a capital-efficient regulatory pathway. The Company believes GEO-MVA has the potential to become an important strategic preparedness asset by providing governments and international public health organizations with an additional, reliable source of MVA vaccine to support biosecurity and orthopoxvirus preparedness.

About CEPI and the Centralised Laboratory Network

CEPI is an innovative partnership between public, private, philanthropic and civil organisations. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need. Central to CEPI’s pandemic-beating plan is the ‘100 Days Mission’ to develop safe, effective and accessible vaccines against new threats in just 100 days. CEPI is seeking $2.5 billion to execute CEPI 3.0, its 2027-2031 strategy which will systematically reduce the likelihood, impact and cost of epidemics and pandemics by driving the 100 Days Mission towards an operational reality. Learn more at CEPI.net.

The Centralised Laboratory Network focuses on the assessment of vaccines against CEPI’s priority list of pathogens including Lassa, Nipah, mpox, MERS, Ebola, Chikungunya, Rift Valley fever and COVID-19.

Laboratory members also support testing of vaccines for other viral threats with epidemic or pandemic potential, like Marburg, and are on standby to help fast-track the assessment of vaccine candidates against a Disease X – a novel or as-of-yet unidentified pathogen. To date, the network has served over 60 vaccine developers to assess their vaccine candidates at all stages of developments, processing over 120,000 samples.

CEPI’s Centralised Laboratory Network members are listed here. Laboratories are selected to join the network based on their capacity, experience and scientific expertise in testing clinical samples using high-quality systems. Since its launch in 2020, CEPI has provided up to US $59 million to fund capability building and collect immunogenicity data in the network.

Data produced by members of the network is sent back to the vaccine developer. Neither CEPI nor the laboratory who assessed the samples owns the data.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on the development of vaccines and immunotherapies addressing high-consequence infectious diseases and solid tumor cancers. GeoVax’s priority program is GEO-MVA, an investigational Modified Vaccinia Ankara (MVA)–based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the fourth quarter of 2026, to address critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness. In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings. GeoVax maintains a global intellectual property portfolio supporting its infectious disease and oncology programs and continues to evaluate strategic partnerships and funding opportunities aligned with its development priorities. For more information, visit www.geovax.com.

Forward-Looking Statements

 This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

 Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Company Contact:

[email protected]

678-384-7220

Media Contact:

Jessica Starman

[email protected]

Release – Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement

Cardiff Oncology, Inc. logo

Research News and Market Data on CRDF

September 14, 2026

PDF Version

Under the terms of the Amendment, all disputed issues are resolved

SAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (NASDAQ: CRDF) (“Cardiff”) and Nerviano Medical Sciences S.r.l. (“NMS”) today announced that they have reached a settlement and amended their 2017 Exclusive License Agreement, resolving all outstanding disputes between the two companies related to the global rights for onvansertib, Cardiff’s lead PLK1 inhibitor drug candidate, and establishing an expanded collaborative framework to support onvansertib’s continued clinical development.

Cardiff and NMS have agreed to a full and mutual release of all claims asserted in the litigation pending in the U.S. District Court for the Southern District of California. Cardiff and NMS plan to jointly request dismissal of all claims with prejudice.

“This Amendment strengthens our long-term rights to onvansertib as a promising treatment for cancer, beginning with first-line RAS-mutated metastatic colorectal cancer,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “We are pleased to be entering into this agreement with NMS, which reflects our shared commitment to bringing onvansertib to patients with high unmet need.”

“We look forward to working with Cardiff to advance onvansertib into a global Phase 3 study in first-line RAS-mutated metastatic colorectal cancer and to bring this therapy to patients,” said Hugues Dolgos, PharmD, Chief Executive Officer of NMS Group S.r.l.

The Parties clarified and expanded on the royalty structure in the License Agreement. The agreement also includes development objectives related to Cardiff’s upcoming Phase 3 program, as well as rights for NMS to appoint a Board observer and join Cardiff’s Scientific Advisory Board.

About Onvansertib
Onvansertib is a highly specific, oral PLK1 inhibitor advancing toward a registrational trial in first-line RAS-mutated mCRC. In a randomized Phase 2 trial, onvansertib in combination with FOLFIRI/bevacizumab (first-line standard-of-care) demonstrated dose-dependent improvements in overall response rate and progression-free survival compared to standard-of-care alone, building on findings from a prior Phase 2 trial in second-line RAS-mutated mCRC. Based on these results, the Company has selected the 30 mg dose of onvansertib in combination with FOLFIRI/bevacizumab for advancement into a registrational trial in first-line patients with RAS-mutated mCRC.

About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Cardiff’s lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated mCRC, addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single-agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.

About NMS
NMS is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative oncology therapies. Building on a long-standing heritage in cancer biology and drug discovery, NMS combines a focused clinical-stage small-molecule portfolio with a differentiated ADC platform and an active discovery engine generating first-in-class oncology programs. NMS has operations in Italy, the United States, China and Hong Kong.

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Cardiff Oncology’s expectations, strategy, plans or intentions. These forward-looking statements are based on Cardiff Oncology’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidate; results of preclinical studies or clinical trials for our product candidate could be unfavorable or delayed; our need for additional financing; risks related to business interruptions, including the outbreak of COVID-19 coronavirus and cyber-attacks on our information technology infrastructure, which could seriously harm our financial condition and increase our costs and expenses; uncertainties of government or third-party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that our product candidate will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that our product candidate will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Cardiff Oncology’s Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Cardiff Oncology does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

For more information regarding Cardiff, please visit https://www.cardiffoncology.com.

Cardiff Investor Contact: 
Candice Masse 
Astr Partners 
[email protected] 

Cardiff Media Contact:
Amy Bonanno
Lyra Strategic Advisory
[email protected]

For more information regarding NMS, please visit https://www.nervianoms.com/

NMS Media Contact: 
[email protected]

Addus HomeCare to Acquire AccentCare Personal Care Division for $275 Million

Addus HomeCare (NASDAQ: ADUS) is expanding its footprint in the home-based care market with an agreement to acquire the personal care division of AccentCare for approximately $275 million.

The transaction covers AccentCare’s personal care operations outside New York and does not include its home health or hospice businesses. The acquired operations serve an average daily census of approximately 13,700 clients across 10 states and are expected to contribute roughly $280 million in annualized revenue to Addus.

Addus said the deal would increase its revenue base by approximately 19% and is expected to be accretive to financial results. The company plans to fund the acquisition through a combination of cash on hand and borrowings under its revolving credit facility.

Expanding Scale in Personal Care

Personal care is already the largest part of Addus’ business.

Unlike skilled home health, which typically involves nurses or therapists providing medically necessary services, personal care generally helps patients with activities of daily living such as bathing, dressing, meal preparation and mobility.

Addus primarily serves elderly, chronically ill and disabled individuals who might otherwise be at greater risk of hospitalization or institutional care. Its payors include government agencies, managed care organizations, insurers and private-pay clients.

That business has also been the company’s primary growth engine. Personal care represented 78.4% of Addus revenue in the second quarter of 2026, while organic revenue in the segment increased 6.8% from a year earlier. Addus has benefited from both increased service volumes and reimbursement increases in important markets including Texas and Illinois.

The AccentCare transaction adds considerable scale to that existing operation.

More Density — and Six New States

The acquisition strengthens Addus in four states where it already has significant personal care operations: Texas, Illinois, California and Arizona.

It also adds operations in Colorado, Georgia, Minnesota, Pennsylvania, Tennessee and Washington, giving Addus entry into six additional markets through the transaction.

For a labor-intensive business like home care, geographic density can matter. Larger local operations can improve caregiver recruiting, scheduling and administrative efficiency while also making a provider more important to managed care organizations and other payors looking for partners capable of serving broad patient populations.

Addus Chairman and CEO Dirk Allison said the acquisition would deepen the company’s presence in key markets while strengthening its ability to work with managed care and value-based care partners.

After the transaction, Addus will be adding those operations to an organization that already serves roughly 62,500 consumers through 264 locations across 24 states.

Why Home-Based Care Continues to Attract Buyers

The transaction also reflects a broader consolidation trend across home-based healthcare.

The long-term investment case is relatively straightforward: the U.S. population is aging, many patients would prefer to receive care at home, and home-based services can often be less expensive than institutional settings such as skilled nursing facilities.

Those characteristics have continued to attract strategic buyers and private-equity-backed operators despite a more difficult reimbursement and labor environment. Industry data show 55 home health and hospice transactions were announced during the first half of 2026, only modestly below the 58 transactions recorded during the same period last year.

Personal care can be particularly attractive because demand is tied closely to long-term demographic trends rather than episodic medical procedures.

The business is not without challenges. Recruiting and retaining caregivers remains difficult across the industry, while reimbursement levels — particularly in Medicaid-funded programs — can have a substantial impact on margins. Buyers have consequently become more selective, placing greater emphasis on operating quality, reimbursement exposure, compliance and local market density.

That environment tends to favor larger operators with established infrastructure and access to capital.

Addus Has Been an Active Consolidator

The AccentCare deal is consistent with a strategy Addus has been pursuing for several years.

The company completed three acquisitions during 2025 and has continued adding operations in 2026, including personal care assets in Indiana. Management has repeatedly said acquisitions remain an integral component of its growth strategy, particularly where transactions allow Addus to increase density in existing markets or enter attractive new geographies.

On the company’s most recent earnings call, Allison said Addus was seeing an increased number of personal care businesses come to market as sellers became more comfortable with the reimbursement environment.

He also indicated that the company remained active in evaluating transactions, suggesting the AccentCare agreement may be part of a broader consolidation strategy rather than a one-off expansion.

The $275 million purchase price is also significant relative to the approximately $280 million in annualized revenue Addus expects to acquire, although revenue alone does not indicate the profitability or ultimate economics of the transaction.

AccentCare Narrows Its Focus

For AccentCare, the agreement represents a partial portfolio reshaping rather than an exit from home-based healthcare.

The company will retain its home health, palliative care and hospice businesses, which together form a large national post-acute care platform. AccentCare says it serves more than 200,000 patients and clients annually across more than 280 locations in 30 states and the District of Columbia.

AccentCare CEO Laura Tortorella said Addus was a natural owner for the personal care operation because of its focus and scale in the segment, while the transaction allows AccentCare to continue concentrating on its remaining care businesses.

Building a Larger Home-Care Platform

For Addus, the strategic rationale is primarily about scale.

The company is adding approximately 13,700 daily clients, $280 million of annualized revenue and a broader geographic footprint to a personal care business that already represents nearly four-fifths of its revenue.

That scale could become increasingly important as home-based healthcare evolves toward larger managed-care relationships and value-based reimbursement arrangements. Larger operators are generally better positioned to invest in technology, caregiver recruitment, compliance and administrative infrastructure while serving patients across multiple markets.

The transaction still requires regulatory approvals and customary closing conditions, and Addus has not yet provided a specific closing date.

If completed as planned, however, the AccentCare acquisition would further establish Addus as one of the larger multi-state personal care providers at a time when demographic trends, healthcare costs and patient preferences continue pushing more care into the home.

Release – GeoVax Provides Nasdaq Listing Update and Reaffirms Focus on Advancing Strategic Priorities

GeoVax, Inc.

Research News and Market Data on GOVX

ATLANTA, GA – September 10, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against high-consequence infectious diseases and solid tumor cancers, today provided an update regarding its Nasdaq listing status and reaffirmed its continued focus on advancing the Company’s key development and strategic priorities.

As previously disclosed, GeoVax requested a hearing before the Nasdaq Hearings Panel (the “Panel”) to appeal the delisting determination the Company received on August 27, 2026, relating to the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The hearing has been scheduled for October 13, 2026.

The Company’s hearing request has stayed any suspension or delisting action pending the hearing and the expiration of any extension period that may be granted by the Panel following the hearing. Accordingly, GeoVax’s common stock is expected to continue to trade on The Nasdaq Capital Market under the symbol “GOVX” at least through that period. At the hearing, GeoVax intends to present its plan to regain and maintain compliance with the applicable Nasdaq listing standards.

David Dodd, Chairman and Chief Executive Officer of GeoVax, commented, “We remain committed to maintaining GeoVax’s Nasdaq listing and look forward to presenting our compliance plan to the Hearings Panel. Importantly, the Nasdaq process does not change our strategic priorities or our focus on execution. We continue to advance GEO-MVA toward its planned pivotal Phase 3 clinical program, pursue opportunities to strengthen our manufacturing and global preparedness capabilities, and engage potential strategic, funding and development partners across our portfolio.”

Mr. Dodd continued, “Our focus remains on building long-term value from GeoVax’s vaccine and immuno-oncology programs while addressing the Company’s near-term corporate and financing priorities. We believe the progress across our programs, together with the growing emphasis on vaccine supply resilience, biodefense preparedness and expanded global access, provides a strong foundation for our continued efforts.”

Continued Focus on Key Strategic Priorities

GeoVax’s priority program is GEO-MVA, an investigational Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial addressing the need for expanded orthopoxvirus vaccine supply and biodefense preparedness.

In parallel, GeoVax continues to pursue manufacturing and product innovations intended to support broader access and preparedness, while evaluating strategic partnerships and funding opportunities aligned with its development priorities.

In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings.

The Company also maintains a broader MVA-based vaccine platform and intellectual property portfolio addressing high-consequence infectious diseases and global health preparedness.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on the development of vaccines and immunotherapies addressing high-consequence infectious diseases and solid tumor cancers. GeoVax’s priority program is GEO-MVA, a Modified Vaccinia Ankara (MVA)–based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026, to address critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness. In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings. GeoVax maintains a global intellectual property portfolio supporting its infectious disease and oncology programs and continues to evaluate strategic partnerships and funding opportunities aligned with its development priorities. For more information, visit www.geovax.com.

Forward-Looking Statements

This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to continue and complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Company Contact:

[email protected]

678-384-7220

Media Contact:

Jessica Starman

[email protected]